Project Grant R21AI189232
Award Date
1/3/25
Completion Date
12/31/26
Dollars Obligated
$215K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92161, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $3,110,884 to the Regents of the University of Michigan to develop next-generation inhibitors of the HIV Nef protein. The goal is to create potent Nef inhibitors that can restore the function of anti-HIV cytotoxic T lymphocytes (CTLs), enabling more effective clearance of HIV-infected cells from latent reservoirs....
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is focused on understanding the mechanisms by which HIV-1 and HIV-2 antagonize the short isoform of the antiviral protein BST2. The $368,750 award, which runs from July 2025 to June 2030, supports research to: 1) probe the mechanisms by which HIV-1 Vpu and HIV-2 Env displace the short BST2 isoform from sites of viral assembly, 2) evaluate the activity...
This federal Project Grant award of $2,505,639 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand the molecular interactions between lentivirus capsids and the nuclear pore complex protein NUP358. The project aims to investigate how the binding of lentiviral capsids, including HIV-1 and HIV-2, to the RBD4-CHD didomain of NUP358 impacts viral nuclear import and replication....
This Project Grant award of $1,454,386.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports fundamental research to better understand the epigenetic regulation of the HIV-1 viral RNA cap. The research aims to define the structural basis of HIV cap hypermethylation and its linkage to modulating host innate immune signaling, with the goal of developing new treatments to neutralize deleterious...
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $714,754 to Northwestern University from November 2024 to October 2029 to conduct research on the role of FEZ protein homologs in early HIV-1 infection. The research aims to develop a detailed structural and functional understanding of how FEZ family members interact with and impact HIV-1 infection, which could guide...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on determining the mechanism by which the cellular protein EHD4 decreases the infectivity of HIV-1 virus particles. The $238,972 award to The Research Foundation For The State University Of New York (RF SUNY) aims to: 1) Characterize how EHD4 blocks the incorporation of HIV-1 envelope glycoproteins GP41 and GP120...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $220,224 to the University of Chicago to computationally investigate key morphological transitions in the HIV-1 life cycle. The research aims to gain a deeper mechanistic understanding of HIV assembly, maturation, and uncoating processes, with a focus on the roles of viral RNA, host cell factors, and...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...
This Project Grant award of $285,816 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research to enhance understanding of ADP-ribosylation (ADPR) and its role in HIV-1 latency and reactivation. The awardee, The Regents of the University of California, San Francisco, will conduct biochemical, proteomic, and cellular assays to identify global proteomic changes to ADPR during HIV-1 latency and reactivation,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to characterize HIV reservoirs in macrophages and investigate mechanisms by which these cells resist antibody-dependent cellular cytotoxicity (ADCC). The $243,713 award to the University of Massachusetts Medical School aims to: 1) determine how HIV accessory proteins Nef and Vpu differentially regulate NK cell...